Cabazitaxel

Extended indication	Cabazitaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
Therapeutic value	Possible equal value
Registration phase	Registered

Product

Active substance	Cabazitaxel
Domain	Oncology and Hematology
Reason of inclusion	Generic
Main indication	Prostate cancer
Extended indication	Cabazitaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
Current proprietary name	Jevtana (Sanofi-Aventis)
Proprietary name	Cabazitaxel Accord
Manufacturer	Accord Healthcare
Mechanism of action	Cytostatic

Registration route	Centralised (EMA)
Submission date	June 2019
Expected Registration	August 2020
Registration phase	Registered
Additional remarks	SPC Jevtana verloopt op 21 maart 2026. Positieve CHMP-opinie in april 2020.

Therapeutic value	Possible equal value

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.